Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein - Test2 - elhamkhani - TriplyDB

Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein

Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein

http://www.wikidata.org/entity/Q33638420

about

γ-H2AX kinetics as a novel approach to high content screening for small molecule radiosensitizers A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies.Phase I Trial of Triapine-Cisplatin-Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers.Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer.Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers Long-Term Disease Control with Triapine-Based Radiochemotherapy for Patients with Stage IB2-IIIB Cervical Cancer.Posttherapy residual disease associates with long-term survival after chemoradiation for bulky stage 1B cervical carcinoma: a Gynecologic Oncology Group study.Molecular Strategies of Deoxynucleotide Triphosphate Supply Inhibition Used in the Treatment of Gynecologic Malignancies Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance.Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers Radiosensitization of human cervical cancer cells by inhibiting ribonucleotide reductase: enhanced radiation response at low-dose rates.Deoxynucleoside salvage facilitates DNA repair during ribonucleotide reductase blockade in human cervical cancers Determination of triapine, a ribonucleotide reductase inhibitor, in human plasma by liquid chromatography tandem mass spectrometry.A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.Management of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone-induced methemoglobinemia.Ribonucleotide reductase inhibitors: a new look at an old target for radiosensitization.Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study.Therapeutic Mechanisms of Treatment in Cervical and Vaginal Cancer.A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer.Elevated ribonucleotide reductase levels associate with suppressed radiochemotherapy response in human cervical cancers.Inhibition of Poly(ADP-Ribose) Polymerase Enhances Radiochemosensitivity in Cancers Proficient in DNA Double-Strand Break Repair Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis Targeting ribonucleotide reductase for cancer therapy.Overexpression of p53R2 is associated with poor prognosis in lung sarcomatoid carcinoma.LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma.p53R2 overexpression in cervical cancer promotes AKT signaling and EMT, and is correlated with tumor progression, metastasis and poor prognosis.Triapine Radiochemotherapy in Advanced Stage Cervical Cancer.Irradiation of pediatric glioblastoma cells promotes radioresistance and enhances glioma malignancy genome-wide transcriptome changes

P2860

Q28480920-F123C164-AA4E-4CEB-A5E2-F76A88CA005D Q33419816-0508F12D-BE3D-4A4E-96DB-2F97D22078CA Q33437008-49D610F8-5E09-436B-B93D-C4ACDD29416E Q33441115-0B46D3A7-A958-4674-A7F6-CC83BEB04C78 Q33658330-B88FA7F9-4A89-43E4-9113-7A0A97CE8A48 Q33721213-E5D272DB-B835-412A-BE3A-F27185600D04 Q33944113-EF24916C-655C-49B5-84BD-75B0B05434EB Q34163791-8CE0C726-AB58-4655-B5B0-2E6CFF8C37AD Q34482362-78D2767B-CA54-44F6-9576-4527A2219451 Q34615592-AD56EF7F-E38C-417A-9D53-FE28D7FEB819 Q34662652-04096C71-620C-4821-9C3C-12DAC56EC499 Q35056458-E3110F92-A6C8-4032-AD41-74E1D407D6AA Q35318609-73ACEE2C-BB40-4C37-882E-D1CA6789D54C Q35560319-98298C02-0EEF-4B91-B107-378A57676472 Q35782691-7907A104-9F99-41E8-9B78-1ACA54DC81E8 Q35796011-2A4810D4-0ECD-4550-B980-597927517968 Q35971759-797BDDE4-99B3-4E83-9881-3F63FCF27F87 Q36112585-797E3016-50E2-40CB-BF37-B11C97B47608 Q36195902-B8F52DA5-19AE-42B3-B660-C657FC1222AE Q36335873-94559646-5DC1-463D-B8CF-3BE85CB5E101 Q36347370-8B219C18-7DB4-452B-AAC5-66EEEA3E9FC9 Q36656132-851B7ADA-4A1F-4052-87A6-2C53C466F97D Q36868936-3C97B9D3-72F2-4871-90CF-AF1A29ABAFC4 Q38148222-B854D428-A338-4974-A0C7-F77C4FE25881 Q47156483-5A68D4B8-3237-4DB0-BA95-A75B0274D408 Q47841713-0273ABB3-EEE9-4BF8-BDD5-595A571B8DFB Q47906170-5A904595-E80B-4AA2-9D3C-B59E6B9B6871 Q55016411-F41B0A52-A38A-4B02-BE5B-357197ABD555 Q57821551-89C7A6AA-D8BA-4554-888D-F6C6BE4EB8D6

P2860

Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein

http://www.wikidata.org/entity/Q33638420

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Modulating radiation resistanc ...... ationally silenced p53 protein

@ast

Modulating radiation resistanc ...... ationally silenced p53 protein

@en

type

label

Modulating radiation resistanc ...... ationally silenced p53 protein

@ast

Modulating radiation resistanc ...... ationally silenced p53 protein

@en

prefLabel

Modulating radiation resistanc ...... ationally silenced p53 protein

@ast

Modulating radiation resistanc ...... ationally silenced p53 protein

@en

P1433

Q33638420-8CBD84C1-E7B1-4AB3-AFFD-66291E1FAA0F

P1476

Q33638420-AEC9CF45-3D4B-431A-8DBA-54E07C4EA7DF

P2093

Q33638420-02171FDE-15AB-465D-A474-66CB32899709

Q33638420-57C4564D-6682-453B-A6A0-1E6BFCC1D94A

Q33638420-D464A221-647E-4EBA-BDAC-C917C78A5E99

Q33638420-F5ACEBF6-8823-4561-8E0F-FB947D746D2D

P2860

Q33638420-044C98E8-F4AC-4413-89C7-BE9F7FF5BDE3

Q33638420-094C1B17-9D60-4264-B4CC-F293A15D9A50

Q33638420-096AC579-131F-4492-981E-014349057311

Q33638420-0D133F53-1EAB-4A9B-A0F2-E5FC84E5F8D0

Q33638420-1476A018-2370-4FEC-BC06-3EB0AEAD17C3

Q33638420-22565E11-486A-4D84-BF0E-1C778488ACCA

Q33638420-2AACA347-AA74-4570-9AB6-F31150B026E3

Q33638420-2FFEA230-0D6F-47D0-A579-84B209DCDF00

Q33638420-349456D7-0DAD-4923-A83E-1695344021A7

Q33638420-3693BAE8-54A0-4629-8FB6-3A91F69E99AA

P304

Q33638420-76A7B137-508F-4641-BCD9-0F5AB26709FC

P31

Q33638420-261D75E6-E4E8-4AE0-961D-17AE4548C84C

P356

Q33638420-EDC966F0-BEBE-422D-A81C-0417030B2A79

P433

Q33638420-A7880F6E-2B47-46E1-BA75-2D642A1B350D

P478

Q33638420-78973C7F-7C72-45C2-90F8-DF197A704CDF

P577

Q33638420-3814708E-FF5B-490B-BA7E-6F7397419DA6

P5875

Q33638420-24265775-E0F1-4EAD-8940-11D47FBB8BE7

P698

Q33638420-31C202C9-5E29-4DE4-BC26-3A5FC756A0CA

P932

Q33638420-F56AAD0A-5FC9-4B93-962C-DBEA0DE402A1

P356

P1433

Radiation Research

P1476

Modulating radiation resistanc ...... ationally silenced p53 protein

@en

P2093

Charles A Kunos

http://www.w3.org/2001/XMLSchema#string

John Pink

http://www.w3.org/2001/XMLSchema#string

Song-mao Chiu

http://www.w3.org/2001/XMLSchema#string

Timothy J Kinsella

http://www.w3.org/2001/XMLSchema#string

P2860

A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage

Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits

Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase

The many substrates and functions of ATM

The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53

Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells

In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase

Effect of high-risk human papillomavirus oncoproteins on p53R2 gene expression after DNA damage

ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage

Regulation of G(2)/M events by Cdc25A through phosphorylation-dependent modulation of its stability

P304

666-676

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1667/RR1858.1

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

172

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40022896

http://www.w3.org/2001/XMLSchema#string

P698

19929413

http://www.w3.org/2001/XMLSchema#string

P932

2818576

http://www.w3.org/2001/XMLSchema#string